A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 278-283

  Van Rompay, Koen K A ^a   Greenier, Jennifer L ^a   Marthas, Marta L ^a,b   Otsyula, Moses G ^a,c   Tarara, Ross P ^a   Miller, Christopher J ^a,b   Pedersen, Niels C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF PRIMATE RESEARCH   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ADEFOVIR; ANTIVIRUS AGENT; DIDANOSINE; GLUTAMINE; LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS ISOLATION; VIRUS MUTANT; VIRUS RESISTANCE; VIRUS VIRULENCE;

EID: 0031039656     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.278     Document Type: Article

References (52)

1. Animann, A. J. 1994. Human immunodeficiency virus infection/ AIDS in children: the next decade. Pediatrics 93:930-935.
2. Angarana, G., L. Monno, A. Appice, A. Giannelli, C. Romalli, C. Fico, and G. Pastore. 1994. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS 8:1013-1014.
3. Boucher, C. A. B., R. van Leeuwen, P. Kellam, P. Schipper, J. Tijnagel, J. M. A. Lange, and B. A. Larder. 1993. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1525-1530.
4. Boyer, P. L., A. L. Ferris, P. Clark, J. Whitmer, P. Frank, C. Tantillo, E. Arnold, and S. H. Hughes. 1994. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. J. Mol. Biol. 243:472-483.
5. Cheeseman, S. H., D. Havlir, M. M. McLaughlin, T. C. Greenough, J. L. Sullivan, D. Hall, S. E. Hattox, S. A. Spector, D. S. Stein, M. Myers, and D. D. Richman. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. 8:141-151.
6. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, D. D. Richman, for the AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
7. Erice, A., D. L. Mayers, D. G. Strike, K. J. Sannerud, F. E. McCutchan, K. Henry, and H. H. Balfour. 1993. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N. Engl. J. Med. 328: 1163-1165.
8. Erice, A., and H. J. Balfour. 1994. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin. Infect. Dis. 18:149-156.
9. Frenkel, L. M., L. E. I. Wagner, L. M. Demeter, S. Dewhurst, R. W. Coombs, B. L. Murante, and R. C. Reichman. 1995. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus. Clin. Infect. Dis. 20:1321-1326.
10. Hermans, P., S. Sprecher, and N. Clumeck. 1993. Primary infection with zidovudine-resistant HIV. N. Engl. J. Med. 329:1123. (Letter.)
11. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
12. Johnson, V. A. 1995. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J. Infect. Dis. 171(Suppl. 2):S140-S149.
13. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
14. + cell decline after sexual transmission of a zidovudine-resistant syncitium-inducing isolate of HIV-1. AIDS 8:1017-1019.
15. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
16. Lohman, B. L., J. Higgins, M. L. Marthas, P. A. Marx, and N. C. Pedersen. 1991. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J. Clin. Microbiol. 29:2187-2192.
17. Maeda, Y., T. Ueno, M. F. Kavlick, T. Shirasaka, R. Yarchoan, and H. Mitsuya. 1996. Emergence of multi-dideoxynucleoside-resistant HIV-1 in patients receiving long-term combination therapy with dideoxynucleosides, abstr. 40. In Abstracts of the Fifth International Workshop on HIV Drug Resistance.
18. Marthas, M. L., K. K. A. Van Rompay, M. Otsyula, C. J. Miller, D. Canfield, N. C. Pedersen, and M. B. McChesney. 1995. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 69:4198-4205.
19. Masquelier, B., E. Lemoigne, I. Pellegrin, D. Douard, B. Sandler, and H. J. A. Fleury. 1993. Primary infection with zidovudine-resistant HIV. N. Engl. J. Med. 329:1123-1124. (Letter.)
20. Montaner, J. S. G., J. Singer, M. T. Schechter, J. M. Raboud, C. Tsoukas, M. O'Shaughnessy, J. Ruedy, K. Nagai, H. Salomon, B. Spira, and M. A. Wainberg. 1993. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 7:189-196.
21. Myers, G., J. A. Berzofsky, B. Korber, R. F. Smith, and G. N. Pavlakis. 1991. Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N.M.
22. Nielsen, K., L. S. Wie, M.-S. Sim, A. Deveikis, M. Keller, E. R. Stiehm, L. M. Frenkel, and Y. J. Bryson. 1995. Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay. J. Infect. Dis. 172:359-364.
23. Ogino, M. T., W. M. Dankner, and S. A. Spector. 1993. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J. Pediatr. 123:1-8.
24. M. Otsyula, M. G., C. J. Miller, M. L. Marthas, K. K. A. Van Rompay, J. R. Collins, N. C. Pedersen, and M. B. McChesney. 1996. Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr. Res. 39:630-635.
25. Quigg, M., G. Darby, and A. J. Leigh Brown. 1996. Zidovudine resistance in recently infected individuals, abstr. 90. In Abstracts of the Fifth International Workshop on HIV Drug Resistance.
26. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37: 1207-1213.
27. Richman, D. D. 1994. Resistance, drug failure, and disease progression. AIDS Res. Hum. Retroviruses 10:901-905.
28. Richman, D. D. 1995. Clinical significance of drug resistance in human immunodeficiency virus. Clin. Infect. Dis. 21(Suppl. 2):S166-S169.
29. Richman, D. D. 1995. Protease uninhibited. Nature 374:494.
30. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shin, M. M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
31. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schlief, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, K. W. Anderson, F. E. Massari, and G. M. Shaw. 1993. A short-term clinical evaluation of L-697,661, a nonnucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
32. Schmit, J.-C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. J. Infect. Dis. 174:962-968.
33. Schmit, J.-C., I. Vanderlinden, L. Ruiz, B. Clotet, P. Hermans, S. Sprecher, V. Arendt, W. Peetermans, T. Harrer, D. Vaira, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1996. Prevalence of multi-drug resistance to dideoxynucleoside (ddN) analogues in patients on ddN combination therapy, abstr. 39. In Abstracts of the Fifth International Workshop on HIV Drug Resistance.
34. Shafer, R., M. Winter, A. Iversen, and T. Merigan. 1996. Genotypic and phenotypic changes during culture of wild-type and multinucleoside resistant HIV-1 strains, abstr. 329. In Abstracts of the Third Conference on Retroviruses and Opportunistic Infections.
35. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. N. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer III, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
36. Shafer, R. W., A. K. N. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, T. C. Merigan, and the AIDS Clinical Trials Group 143 Virology Team. 1995. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infectcd subjects to zidovudine and didanosine. J. Infect. Dis. 172:70-78.
37. Shirasaka, T., R. Yarchoan, M. C. O'Brien, R. N. Husson, B. D. Anderson, E. Kojima, T. Shimada, S. Broder, and H. Mitsuya. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90:562-566.
38. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
39. Siegrist, C. A., S. Yerly, L. Kaiser, C. A. Wyler, and L. Perrin. 1994. Mother to child transmission of zidovudine-resistant HIV-1. Lancet 344:1771-1772.
40. Sönnerborg, A., B. Johansson, S. Ayehunie, and I. Jolander. 1993. Transmission of zidovudine-resistant HIV-1. AIDS 7:1684-1685.
41. Sutjipto, S., N. C. Pedersen, C. J. Miller, M. B. Gardner, C. V. Hanson, A. Gettie, M. Jennings, J. Higgins, and P. A. Marx. 1990. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol. 64:2290-2297.
42. Tudor-Williams, G., M. H. St. Clair, R. E. McKinney, M. Maha, E. Walter, S. Santacroce, M. Mintz, K. O'Donnell, T. Rudoll, C. L. Vavro, E. M. Connor, and C. M. Wilfert. 1992. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 339:15-19.
43. Ueno, T., T. Shirasaka, and H. Mitsuya. 1995. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J. Biol. Chem. 270:23605-23611.
44. Van Rompay, K. K. A., and J. M. Cherrington. Unpublished data.
45. Van Rompay, K. K. A., M. L. Marthas, R. A. Ramos, C. P. Mandell, E. K. McGowan, S. M. Joye, and N. C. Pedersen. 1992. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother. 36:2381-2386.
46. Van Rompay, K. K. A., M. Otsyula, M. L. Marthas, and N. C. Pedersen. 1994. Simian immunodeficiency virus infection of newborn and infant rhesus macaques: an animal model for testing antiretroviral drugs. Int. Antiviral News 2:5-6.
47. Van Rompay, K. K. A., M. G. Otsyula, M. L. Marthas, C. J. Miller, M. B. McChesney, and N. C. Pedersen. 1995. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob. Agents Chemother. 39:125-131.
48. Van Rompay, K. K. A., M. G. Otsyula, R. P. Tarara, D. R. Canfield, C. J. Berardi, M. B. McChesney, and M. Marthas. 1996. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J. Infect. Dis. 173:1327-1335.
49. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
50. Wainberg, M. A., Z. Gu, Q. Gao, E. Arts, R. Geleziunas, S. Bour, R. Beaulieu, C. Tsoukas, J. Singer, and J. Montaner. 1993. Clinical correlates and molecular basis of HIV drug resistance. J. Acquired Immune Defic. Syndr. 6(Suppl. 1):S36-S46.
51. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
52. Yerly, S., A. Rakik, S. Kinloch, B. Hirschel, and L. Perrin. 1996. Persistence of ZDV resistant mutations in patients with primary HIV infection, abstr. 82. In Abstracts of the Fifth International Workshop on HIV Drug Resistance.